Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest EPS Growth Forecast For Next 5 Years

Below are the top mid-cap biotechnology stocks on the NYSE and the NASDAQ in terms of EPS growth forecast for the next five years.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) earnings per share growth forecast for the next five years is 46.09 percent. Alnylam Pharmaceuticals’ trailing-twelve-month revenue is $62.20 million.

Dyax Corp. (NASDAQ: DYAX) EPS growth forecast for the next five years is 30.70 percent. Dyax’s trailing-twelve-month gross margin is 87.10 percent.

Insys Therapeutics Inc (NASDAQ: INSY) EPS growth forecast for the next five years is 28.00 percent. Insys Therapeutics’ PEG ratio is 2.64.

China Biologic Products Inc (NASDAQ: CBPO) earnings per share growth forecast for the next five years is 25.41 percent. China Biologic Products’ trailing-twelve-month ROE is 32.90 percent.

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.